| Authors: |
El Zarif T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Yale School of Medicine, New Haven, Connecticut., Meador CB; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Qiu X; Department of Medicine, Yale School of Medicine, New Haven, Connecticut., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Davidsohn MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Lakshminarayanan G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., McClure HM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Canniff J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Li R; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Banwait MK; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Semaan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Eid M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Long H; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Hung YP; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Piotrowska Z; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Hata AN; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. |
